MIGHTY, it appears I owe you an apology and consider this such, please.
I've just written two long responses outlining my thinking up to this point, only to have my pc seize up with this new 8.1 software, and both got lost, so i've given up!
I will say that re-evaluating the upcoming financial landscape facing the company,especially and crucially in light of the Board approved default - a very serious action and sign - coupled with the debt to be incurred in the upcoming litigation settlement involving A/G, Camofi, Aaronson and WARF and the qualifying statements for the coming months in the 10K and in Myles conference call statements and inferences, I share your serious concerns. C
Couple this with no contract for Lanza and unfilled key positions and Myles stated need for a stable/high share price to maximize their relationship with Lincoln, all seems to suggest bankruptcy is realistically in the cards.
I've alluded to this before in posts and privately.
A new company/relationship with another firm, etc., (please, not more share dilution), will shed much lingering, unending debt, allow the company to continue it's promising clinicals, but the big downside, of course, bankruptcy for we retail shareholders means ZERO share price and a big loss for so many of us.
And so this journey of the past 10 years seems to go.
I dread every morning now having to read upcoming company releases.
Perhaps a truly experienced/degreed investment financial individual has some additional thoughts to share?
News 
Market Data 
Discover 
